Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Q4 Editor’s Picks: Clinical Trial Regulation

Executive Summary

Coverage of clinical trial policy included commentary on rapid growth of the PD-1 pipeline by both US and China regulators; case studies and discussion of trial strategies including RWE, pediatric studies and decentralized trials; and US FDA commissioner-nominee Robert Califf’s R&D expertise.

You may also be interested in...



Editor's Note: Please Help Pink Sheet Serve You Best

Please take our brief reader survey to help us better understand your content and delivery needs.

Editor’s Choice: Notable Pink Sheet Articles From Q3

A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Topics

Latest News
UsernamePublicRestriction

Register

PS145571

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel